GEORGIA BIOMEDICAL PARTNERSHIP

GEORGIA LIFE SCIENCES SURVEY

2008

GENERAL INFORMATION

COMPANY ID:

1 Years in business in Georgia






2 Year the company was founded

3 Location where company was founded

City State Country

4 Location of corporate headquarters

City State Country

5 Does your company have any university affiliations?


If YES, please specify:

Universities

Kind of affiliation (please specify)

6 Number of paid employees in Georgia (check and/or specify)

More than 250

7 Industry classification

Primary industry (Check ONE) Secondary industries (check all that apply)
1 Manufacturing 1 Manufacturing
2 Research and Development 2 Research and Development
  2.1 Biotechnology   2.1 Biotechnology
3 Medical and Diagnostic Laboratories 3 Medical and Diagnostic Laboratories
4 Blood and Organ Banks 4 Blood and Organ Banks
5 Sales/Marketing/Business Services 5 Sales/Marketing/Business Services

6 Other (please specify )

6 Other (please specify )

8-15 Company product/focus in the current year

Primary product Secondary products
1 Pharmaceuticals/therapeutics go to Q9 1 Pharmaceuticals/therapeutics go to Q9
2 Biopharmaceuticals go to Q9 2 Biopharmaceuticals go to Q9
3 Diagnostics go to Q10 3 Diagnostics go to Q10
4 Biologics go to Q11 4 Biologics go to Q11
5 Medical devices go to Q12 5 Medical devices go to Q12
6 Platform technology/Discovery go to Q13 6 Platform technologies/Discovery go to Q13
7 Industrial go to Q14 7 Industrial go to Q14
8 Agricultural go to Q14 8 Agricultural go to Q14
9 Biofuel/Bioenergy go to Q14 9 Biofuel/Bioenergy go to Q14
10 General research technologies go to Q13 10 General research technologies go to Q13

11 Services go to Q15

11 Services go to Q15
12 Other (please specify) 12 Other (please specify)
   

9 Pharmaceutical/Therapeutics OR Biopharmaceutical products: (check all that apply)

1 Neuropharmacological 11 Ophthalmologic
2 Cardio-Renal 12 Oncologic
3 Metabolic 13 Pulmonary
4 Endocrine 14 Anesthetic
5 Gastrointestinal 15 Addiction
6 Coagulation 16 Reproductive/Urologic
7 Medical imaging 17 Anti-Viral
8 Radiopharmaceutical 18 Pathogen/Immunologic
9 Anti-Infective 19 Dermatologic
10 Inflammatory/Analgesic 20 Dental
21Other (please specify )

10 Diagnostic products: (check all that apply)

1 Neuropharmacological 11 Ophthalmologic
2 Cardio-Renal 12 Oncologic
3 Metabolic 13 Pulmonary
4 Endocrine 14 Anesthetic
5 Gastrointestinal 15 Addiction
6 Coagulation 16 Reproductive/Urologic
7 Medical imaging 17 Anti-Viral
8 Radiopharmaceutical 18 Pathogen/Immunologic
9 Anti-Infective 19 Dermatologic
10 Inflammatory/Analgesic 20 Dental
21Other (please specify )

11 Biological products: (check all that apply)

1 Blood 4 Allergenics
2 Vaccines 5 Biological therapeutics
3 Tissue 6 Other (please specify)

12 Medical device products: (check all that apply)

1 General, restorative 4 Respiratory 7 Clinical laboratory 10 Dental
2 Neurological 5 Reproductive/abdominal 8 Ophthalmic 11 Infection control
3 Cardiovascular 6 Radiological 9 ENT devices 12 Hospital devices
13 Other (please specify )

13 Platform Technology/Discovery products, General research technologies: tools used (check all that apply)

1 Microchip technology 4 Nanotechnology
2 Cell analysis and separation 5 Bioinformatics
3 Microfluidic-based 6 General research technologies (please specify)
  7 Other (please specify )

14 Industrial Agricultural Biofuels/Bioenergy products: (check appropriate box and specify)

Please specify

15 Services

Please specify:

FACILITIES AND PRODUCTION

16 Approximate square footage of facilities in Georgia (aggregate)

Less than 10,000 51,000-100,000
10,000-50,000 100,000 or more

17 Number of products per development stage (provide a number OR choose Not Applicable)

Not applicable

Human drugs (FDA regulated)
Other products
Devolopment stage Number of products Devolopment stage Number of products
1 R&D 1 R&D
2 Preclinical 2 In approval process
3 IND 3 Marketed products
4 Phase I    
5 Phase II    
6 Phase III    
7 Marketed products    

18 Number of new products to be marketed (please provide a number)

Not applicable  
  Number of products
1 In 6 months or less
2 In 6 months to 1 year
3 In 1 to 3 years
4 In 3 to 5 years
5 In 5 years or more

19 Percentage of marketed products manufactured in Georgia

Not applicable

20 Type of marketed drugs or diagnostics currently manufactured in Georgia

Not applicable
1 Neuropharmacological 7 Radiopharmaceutical 13 Anesthetic
2 Cardio-Renal 8 Anti-Infective 14 Addiction
3 Metabolic/Endocrine 9 Inflammatory/Analgesic 15 Reproductive/Urologic
4 Gastrointestinal 10 Ophthalmologic 16 Anti-Viral
5 Coagulation 11 Oncologic 17 Pathogen/Immunologic
6 Medical imaging 12 Pulmonary 18 Dermatologic
    19 Dental
20 Other (please specify )

21 Type of marketed medical devices currently manufactured in Georgia

Not applicable
1 General, restorative 4 Respiratory 7 Clinical laboratory 10 Dental
2 Neurological 5 Reproductive/abdominal 8 Ophthalmic 11 Infection control
3 Cardiovascular 6 Radiological devices 9 ENT devices 12 Hospital devices
13 Other (please specify )

22 Other marketed products currently manufactured in Georgia

Not applicable

1 Biological products (please specify)
2 Industrial products (please specify)
3 Agricultural products (please specify)
4 Biofuel/bioenergy products (please specify)

Manufacturing appeal of Georgia (please rate 1-5, 1=No appeal, 5=Very appealing)

1 Drugs 2 Medical devices 3 Other

 

FINANCIAL INFORMATION

23 Is your company publicly traded?


24 FY 2007 revenues/sales

24.1 Generated by Georgia operations only:

Between $ 51 and $100 million
Between $ 101 and $ 500 million
More than $500 million

24.2 Global revenues/sales: (please specify)

25 FY 2007 income

25.1 Generated by Georgia operations only

Loss
$ 0 to $ 5 million
$ 6 to $ 10 million

25.2 All operations income: (please specify)

26 Amount of capital raised in 2005-2007

2005-2006: $ 2007: $

27 Funding sources for capital raised in 2005-2007 (check all that apply)

1 Founders, family, friends 6 VC funding
2 Private equity/Partnerships 7 Early stage (Series A-B)
3 Public offering 8 Mid stage (Series C-D)
4 Grants 9 Late stage (Series E) 9 Late stage (Series E)
5 Angels  

28 Amount of capital raised to date in 2008

$

29 Funding sources for capital already raised to date in 2008 (check all that apply)

1 Founders, family, friends 6 VC funding
2 Private equity/Partnerships 7 Early stage (Series A-B)
3 Public offering 8 Mid stage (Series C-D)
4 Grants 9 Late stage (Series E)
5 Angels  

30 Amount of capital to be raised during remainder of 2008

$

31 Funding sources for capital raised to be raised during remainder of 2008 (check all that apply)

1 Founders, family, friends 6 VC funding
2 Private equity/Partnerships 7 Early stage (Series A-B)
3 Public offering 8 Mid stage (Series C-D)
4 Grants 9 Late stage (Series E)
5 Angels  

32 In-house strategy (check all that apply)

1 R&D 4 Sales/Marketing
2 Clinical trials 5 Distribution

3 Manufacturing

 

33 Partnership/outsourcing strategy (check all that apply)

1 R&D 4 Sales/Marketing
2 Clinical trials 5 Distribution
3 Manufacturing  

34 Currently seeking partnership opportunities



If yes, please specify the kind of partnership sought: Funding R&D

Other(please specify)

GEORGIA BUSINESS CLIMATE

FOR QUESTIONS 35-37 Please assign an importance weight of 1 to 5 to each item, based on the following:

1 – Not important
2 – Slightly important
3 – Moderately important
4 – Very important
5 – Extremely important/critical

35 Strengths and weaknesses in conducting business in Georgia

 

Importance to your company (please assign weight 1-5)

Is this a strength OR weakness in Georgia?
Leave blank if neutral
Strength
Weakness
1 Proximity to academic institutions/Research facilities
2 Availability of skilled researchers
3 Availability of skilled technicians
4 Availability of skilled managers
5 Availability and cost of skilled manufacturing labor
6 Availability and cost of land
7 Availability of suitable space and facilities
8 Availability/Quality of service providers
9 Regulatory/legislative environment
10 Access to capital
11 Access to government financial incentives and support
12 Quality of life
13 Cost of living (e.g., housing)
14 Infrastructure (e.g., traffic, water, energy, etc.)
15 State's image
16 Other (please specify)

36 Most significant infrastructure issues: (Please assign weight 1-5)

1 Traffic 4 Water: cost availability
2 Energy: cost availability 5 Land use
3 Airport 6 Other (please specify )

37 Most significant state policy and regulatory concerns: (Please assign weight 1-5)

(please specify)
1 R&D regulations/Bioethics 4 Environmental regulations
2 Capital formation 5 Tort reform
3 Tax policy and incentives 6 Public Education
Other (please, specify)

38 Education/Work Force: Please indicate your support for applied masters programs in biotechnology

1 Interested in hiring graduates of applied programs

2 Interested in providing unpaid internships

3 Interested in providing paid internships

4 Interested in providing financial support to the program

5 No interest whatsoever

39 Anticipated changes in workforce in 2008-09 (please check appropriate boxes and provide number)

Category of worker
Expand employment in 2008-09
Number
Reduce employment in 2008-09
Number
1 Ph.D./M.S. Scientists
2 Bench technologists
3 Manufacturing workers
4 Senior management
5 Management
6 Regulatory/Legal
7 Sales/Marketing
8 Office support
9 Other: (please specify)

40 What life sciences companies outside Georgia would you encourage the Georgia Department of Economic Development to contact with a recruitment message?

Do you have a relationship with this company ?



If so, may we share your contact information with the Georgia Dept. of Economic Development?



Companies and locations of headquarters:

Survey Participant: This information will be kept confidential.

Name:

Title:

Company:

Comments (optional):